Free Trial
NASDAQ:UPB

Upstream Bio Q3 2024 Earnings Report

Upstream Bio logo
$16.00 +0.16 (+1.01%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$15.69 -0.31 (-1.94%)
As of 08/8/2025 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Upstream Bio EPS Results

Actual EPS
-$6.96
Consensus EPS
-$0.58
Beat/Miss
Missed by -$6.38
One Year Ago EPS
N/A

Upstream Bio Revenue Results

Actual Revenue
$0.61 million
Expected Revenue
$0.83 million
Beat/Miss
Missed by -$220.00 thousand
YoY Revenue Growth
N/A

Upstream Bio Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
7:00AM ET

Upstream Bio Earnings Headlines

William Blair Lowers Earnings Estimates for Upstream Bio
#1 Pre-IPO Opportunity For 2025 [Take Action Now!]
James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opportunity is taking shape—one tied to what could be the largest IPO in history: Elon Musk’s Starlink. With the IPO rumored to launch as soon as this year, James has uncovered a backdoor method to potentially profit before it goes public—starting with as little as $50.
Upstream Bio (UPB) Q2 R&D Soars 169%
Upstream Bio, Inc. reports Q2 results
See More Upstream Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email.

About Upstream Bio

Upstream Bio (NASDAQ:UPB), a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

View Upstream Bio Profile

More Earnings Resources from MarketBeat